Read more from Darrell E. White
Treating the ocular surface was once again the major emphasis of an incredibly large number of talks at the 2014 American Society of Cataract and Refractive Surgery meeting in Boston, and a hot topic was point-of-service testing. Some of this is old news to those of you who have been treating dry eye syndrome (DES) and ocular surface disease (OSD), even if you’ve just been reading my drivel. There are two parts of this that I find fascinating. First, that it’s still news that treating the ocular surface is so vital to the care of so many patients, and second, that there is still pushback from even long-established OSD programs to adopt point-of-service testing.
Chris Starr reported on an ASCRS survey with some very surprising results. The vast majority of anterior segment docs still view the treatment of DES as an inconvenience. Like, 80% of anterior segment docs! There appears to be an age element at play; docs with fewer than 10 years in practice appear more likely to treat DES and to not view it as a nuisance. The use of point-of-service testing (tear osmolarity, surface inflammation, viral detection) seemed to mirror these trends. Get the whole story